NCT06550648Completed
Evaluation of the Role of Epstein-Bar Virus in Patients With Pulmonary Arterial Hypertension
Source: ClinicalTrials.gov · Last updated 13 Aug 2024
Brief summary (registry, in English)
Evaluate the role of Epstein-Barr virus infection in PAH (Idiopathic and connective tissue disease). This by obtaining a blood sample from the PAH patients undergoing right heart cathetrization as well as obtaining the endothelial cells from the balloon tipped catheters and extracting the EBV virus to detect its presence. IgG, IgM and PCR for EBV tests will be done.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 78 (actual)
- First submitted
- 19 Jul 2024
- Start date
- 1 May 2023
- Primary completion date
- 30 Mar 2024
- Lead sponsor
- Cairo University
- NCT number
- NCT06550648
What you commit to
- Study type: Observational
- Participants enrolled: 78
- From 1 May 2023 to the primary completion date, 30 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other Groups of Pulmonary hypertension Patients refusing written consent or participation
Who the study is looking for
- Group 1 PAH (Idiopathic ) Group 1 PAH ( Connective tissue disease including SLE, Systemic sclerosis and mixed connective tissue disease) Above 18 years
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cairo University- Faculty Of Medicine Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.